Therefore, patients with AIS whose Lp-PLA2 level is greater than 184.36 ng/ml warrant timely screening for CMBs, delay or reduce the occurrence of CMBs by controlling risk factors, so as to reduce the risk of stroke occurrence and recurrence and improve the prognosis of stroke. Here, PLA2G7 is linked to Stroke.